Weishuai An1, Yongsheng Yu1, Yuefan Zhang2, Zhigang Zhang3, Yunhua Yu4, Xianxian Zhao1. 1. Department of Cardiovasology, Changhai Hospital, Second Military Medical University, Shanghai, China. 2. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China. 3. Department of Cardiology, Putuo Center Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. 4. Department of Geriatrics, Fuzhou General Hospital, Fujian Medical University, Fuzhou, China.
Abstract
BACKGROUND AND PURPOSE: Myocardial infarction (MI) is one of the leading causes of death in China and often results in the development of heart failure. In this work, we tested the therapeutic role of Interleukin-19 (IL-19) in mice with MI and investigated the underlying molecular mechanism. EXPERIMENTAL APPROACH: Mice were subjected to MI by ligation of left anterior descending coronary artery (LAD) and treated with IL-19 (10ng g-1 ; i.p.). KEY RESULTS: Protein expression of IL-19 and its receptor in myocardium were upregulated 24 hrs post-MI in male mice. IL-19 treatment decreased infarct and apoptosis in myocardium, accompanied by enhanced haem oxygenase-1 (HO-1) activities and reduced malondialdehyde (MDA) formation. Pretreatment with IL-19 upregulated HO-1 expression in cultured neonatal mouse ventricular myocytes and attenuated oxygen-glucose deprivation (OGD)-induced injuries in vitro. Furthermore, IL-19 preserved cardiac function and improved survival of mice with MI. IL-19 reduced inflammatory infiltrates and suppressed formation of TNF-α, IL-1β, and IL-6. More importantly, IL-19 inhibited polarization toward proinflammatory M1 macrophages and stimulated M2 macrophage polarization in myocardium of mice with MI. IL-19 enhanced protein levels of vascular endothelial growth factor (VEGF) and promoted angiogenesis in myocardium of mice with MI. In addition, IL-19 treatment increased DNA-binding of the transcription factor STAT3 in myocardium of mice with MI. CONCLUSIONS AND IMPLICATIONS: Treatment with exogenous IL-19 attenuated acute ischemic injury and improved survival of mice with MI. The mechanisms underlying these effects involved induction of HO-1, M2 macrophage polarization, angiogenesis, and STAT3 activation.
BACKGROUND AND PURPOSE:Myocardial infarction (MI) is one of the leading causes of death in China and often results in the development of heart failure. In this work, we tested the therapeutic role of Interleukin-19 (IL-19) in mice with MI and investigated the underlying molecular mechanism. EXPERIMENTAL APPROACH: Mice were subjected to MI by ligation of left anterior descending coronary artery (LAD) and treated with IL-19 (10ng g-1 ; i.p.). KEY RESULTS: Protein expression of IL-19 and its receptor in myocardium were upregulated 24 hrs post-MI in male mice. IL-19 treatment decreased infarct and apoptosis in myocardium, accompanied by enhanced haem oxygenase-1 (HO-1) activities and reduced malondialdehyde (MDA) formation. Pretreatment with IL-19 upregulated HO-1 expression in cultured neonatal mouse ventricular myocytes and attenuated oxygen-glucose deprivation (OGD)-induced injuries in vitro. Furthermore, IL-19 preserved cardiac function and improved survival of mice with MI. IL-19 reduced inflammatory infiltrates and suppressed formation of TNF-α, IL-1β, and IL-6. More importantly, IL-19 inhibited polarization toward proinflammatory M1 macrophages and stimulated M2 macrophage polarization in myocardium of mice with MI. IL-19 enhanced protein levels of vascular endothelial growth factor (VEGF) and promoted angiogenesis in myocardium of mice with MI. In addition, IL-19 treatment increased DNA-binding of the transcription factor STAT3 in myocardium of mice with MI. CONCLUSIONS AND IMPLICATIONS: Treatment with exogenous IL-19 attenuated acute ischemic injury and improved survival of mice with MI. The mechanisms underlying these effects involved induction of HO-1, M2 macrophage polarization, angiogenesis, and STAT3 activation.
Authors: Ewa Zajac; Bernhard Schweighofer; Tatyana A Kupriyanova; Anna Juncker-Jensen; Petra Minder; James P Quigley; Elena I Deryugina Journal: Blood Date: 2013-10-30 Impact factor: 22.113
Authors: Michael J Curtis; Steve Alexander; Giuseppe Cirino; James R Docherty; Christopher H George; Mark A Giembycz; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Yong Ji; David J MacEwan; Christopher G Sobey; S Clare Stanford; Mauro M Teixeira; Sue Wonnacott; Amrita Ahluwalia Journal: Br J Pharmacol Date: 2018-04 Impact factor: 8.739
Authors: S F Yet; R Tian; M D Layne; Z Y Wang; K Maemura; M Solovyeva; B Ith; L G Melo; L Zhang; J S Ingwall; V J Dzau; M E Lee; M A Perrella Journal: Circ Res Date: 2001-07-20 Impact factor: 17.367
Authors: Xiaoli Liu; Alok S Pachori; Christopher A Ward; J Paul Davis; Massimiliano Gnecchi; Deling Kong; Lunan Zhang; Jared Murduck; Shaw-Fang Yet; Mark A Perrella; Richard E Pratt; Victor J Dzau; Luis G Melo Journal: FASEB J Date: 2006-02 Impact factor: 5.191
Authors: Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet Journal: J Exp Med Date: 2007-11-19 Impact factor: 14.307
Authors: Fotios G Pitoulis; Raquel Nunez-Toldra; Ke Xiao; Worrapong Kit-Anan; Saskia Mitzka; Richard J Jabbour; Sian E Harding; Filippo Perbellini; Thomas Thum; Pieter P de Tombe; Cesare M Terracciano Journal: Cardiovasc Res Date: 2022-02-21 Impact factor: 10.787